Design, synthesis and molecular docking of new [1,2,4] triazolo[4,3-a]quinoxaline derivatives as anticancer agents targeting VEGFR-2 kinase

[1]  H. Alkahtani,et al.  New bis([1,2,4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, in silico studies, and anticancer evaluation. , 2021, Bioorganic chemistry.

[2]  I. Eissa,et al.  Discovery of thieno[2,3-d]pyrimidine-based derivatives as potent VEGFR-2 kinase inhibitors and anti-cancer agents. , 2021, Bioorganic chemistry.

[3]  K. Jamil,et al.  Identification of novel allosteric binding sites and multi-targeted allosteric inhibitors of receptor and non-receptor tyrosine kinases using a computational approach , 2021, Journal of biomolecular structure & dynamics.

[4]  M. Alanazi,et al.  New quinoxaline derivatives as VEGFR-2 inhibitors with anticancer and apoptotic activity: Design, molecular modeling, and synthesis. , 2021, Bioorganic chemistry.

[5]  M. El-Zahabi,et al.  Design, synthesis and molecular modeling of new quinazolin-4(3H)-one based VEGFR-2 kinase inhibitors for potential anticancer evaluation. , 2021, Bioorganic chemistry.

[6]  Khaled El-Adl,et al.  [1,2,4]Triazolo[4,3-a]quinoxaline and [1,2,4]triazolo[4,3-a]quinoxaline-1-thiol-derived DNA intercalators: design, synthesis, molecular docking, in silico ADMET profiles and anti-proliferative evaluations , 2021 .

[7]  Wael A Alanazi,et al.  Design, synthesis, docking, ADMET studies, and anticancer evaluation of new 3-methylquinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers , 2021, Journal of enzyme inhibition and medicinal chemistry.

[8]  M. Alanazi,et al.  Discovery of new VEGFR-2 inhibitors based on bis([1, 2, 4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as anticancer agents and apoptosis inducers , 2021, Journal of enzyme inhibition and medicinal chemistry.

[9]  M. Elsohly,et al.  Design, molecular docking, in vitro, and in vivo studies of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors with potential activity against hepatocellular carcinoma. , 2020, Bioorganic chemistry.

[10]  Khaled El-Adl,et al.  Design, synthesis, molecular docking and anti-proliferative evaluations of [1,2,4]triazolo[4,3-a]quinoxaline derivatives as DNA intercalators and Topoisomerase II inhibitors. , 2020, Bioorganic chemistry.

[11]  M. Elsohly,et al.  Discovery of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors: Design, synthesis, and anti-proliferative evaluation. , 2020, Bioorganic chemistry.

[12]  B. Escudier,et al.  TiNivo: Safety and Efficacy of Tivozanib-Nivolumab Combination Therapy in Patients with Metastatic Renal Cell Carcinoma. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  H. Luesch,et al.  Discovery of new pyrimidine-5-carbonitrile derivatives as anticancer agents targeting EGFRWT and EGFRT790M. , 2020, Organic & biomolecular chemistry.

[14]  I. Eissa,et al.  Design, efficient synthesis, docking studies, and anticancer evaluation of new quinoxalines as potential intercalative Topo II inhibitors and apoptosis inducers. , 2020, Bioorganic chemistry.

[15]  I. Eissa,et al.  Design, synthesis, and biological evaluation of new challenging thalidomide analogs as potential anticancer immunomodulatory agents. , 2020, Bioorganic chemistry.

[16]  I. Eissa,et al.  Design, synthesis, molecular docking and anticancer evaluations of 5-benzylidenethiazolidine-2,4-dione derivatives targeting VEGFR-2 enzyme. , 2020, Bioorganic chemistry.

[17]  Liu Yang,et al.  Screening of Some Sulfonamide and Sulfonylurea Derivatives as Anti-Alzheimer’s Agents Targeting BACE1 and PPARγ , 2020 .

[18]  Amy Brock,et al.  A hybrid model of tumor growth and angiogenesis: In silico experiments , 2020, PloS one.

[19]  Abdullah A. Elgazar,et al.  Sulfonamide-based ring-fused analogues for CAN508 as novel carbonic anhydrase inhibitors endowed with antitumor activity: Design, synthesis, and in vitro biological evaluation. , 2020, European journal of medicinal chemistry.

[20]  C. Porta,et al.  Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. , 2019, The Lancet. Oncology.

[21]  M. Elsohly,et al.  Design, synthesis, molecular modeling, in vivo studies and anticancer evaluation of quinazolin-4(3H)-one derivatives as potential VEGFR-2 inhibitors and apoptosis inducers. , 2019, Bioorganic chemistry.

[22]  I. Eissa,et al.  Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of phthalimide-sulfonylurea hybrids as PPARγ and SUR agonists. , 2019, Bioorganic chemistry.

[23]  N. Farag,et al.  3D-QSAR pharmacophore modelling, virtual screening and docking studies for lead discovery of a novel scaffold for VEGFR 2 inhibitors: Design, synthesis and biological evaluation. , 2019, Bioorganic chemistry.

[24]  Khaled El-Adl,et al.  Design, synthesis, in silico ADMET profile and GABA‐A docking of novel phthalazines as potent anticonvulsants , 2019, Archiv der Pharmazie.

[25]  Mohamed A. Zeidan,et al.  Design, synthesis and docking study of novel picolinamide derivatives as anticancer agents and VEGFR-2 inhibitors. , 2019, European journal of medicinal chemistry.

[26]  M. Shirley.  Fruquintinib: First Global Approval , 2018, Drugs.

[27]  Khaled El-Adl,et al.  Phthalazine-1,4-dione derivatives as non-competitive AMPA receptor antagonists: design, synthesis, anticonvulsant evaluation, ADMET profile and molecular docking , 2018, Molecular Diversity.

[28]  F. Halaweish,et al.  Novel series of 6-(2-substitutedacetamido)-4-anilinoquinazolines as EGFR-ERK signal transduction inhibitors in MCF-7 breast cancer cells. , 2018, European journal of medicinal chemistry.

[29]  G. Khodarahmi,et al.  Synthesis and cytotoxic evaluation of some novel quinoxalinedione diarylamide sorafenib analogues , 2018, Research in pharmaceutical sciences.

[30]  A. Jahanian-Najafabadi,et al.  Biological evaluation, docking and molecular dynamic simulation of some novel diaryl urea derivatives bearing quinoxalindione moiety , 2017, Research in pharmaceutical sciences.

[31]  D. Frezzetti,et al.  Vascular Endothelial Growth Factor A Regulates the Secretion of Different Angiogenic Factors in Lung Cancer Cells , 2016, Journal of cellular physiology.

[32]  Julio Caballero,et al.  Study of the Differential Activity of Thrombin Inhibitors Using Docking, QSAR, Molecular Dynamics, and MM-GBSA , 2015, PloS one.

[33]  S. Zada,et al.  Indoline ureas as potential anti-hepatocellular carcinoma agents targeting VEGFR-2: Synthesis, in vitro biological evaluation and molecular docking. , 2015, European journal of medicinal chemistry.

[34]  M. Noolvi,et al.  Design and synthesis of VEGFR-2 tyrosine kinase inhibitors as potential anticancer agents by virtual based screening , 2015 .

[35]  Loretta Fala.  Lenvima (Lenvatinib), a Multireceptor Tyrosine Kinase Inhibitor, Approved by the FDA for the Treatment of Patients with Differentiated Thyroid Cancer. , 2015, American health & drug benefits.

[36]  Nasser S. M. Ismail,et al.  Design, synthesis and biological evaluation of type-II VEGFR-2 inhibitors based on quinoxaline scaffold. , 2014, Bioorganic chemistry.

[37]  A. Mansour,et al.  Design and synthesis of some novel 2-(3-methyl-2-oxoquinoxalin-1(2H)-yl)-N-(4-(substituted)phenyl)acetamide derivatives for biological evaluation as anticonvulsant agents , 2013 .

[38]  Zhiqiang Bai,et al.  Development and strategies of VEGFR-2/KDR inhibitors. , 2012, Future medicinal chemistry.

[39]  D. Strumberg,et al.  Regorafenib for cancer , 2012, Expert opinion on investigational drugs.

[40]  Jeong Heo,et al.  Sorafenib in liver cancer , 2012, Expert opinion on pharmacotherapy.

[41]  D. Zopf,et al.  Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity , 2011, International journal of cancer.

[42]  K. Syrigos,et al.  The role of angiogenesis in solid tumours: an overview. , 2009, European journal of internal medicine.

[43]  K. Ballmer-Hofer,et al.  Structure and function of VEGF receptors , 2009, IUBMB life.

[44]  P. A. Harris,et al.  Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors. , 2007, Journal of medicinal chemistry.

[45]  E. Raymond,et al.  Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST) , 2007, Therapeutics and clinical risk management.

[46]  S. Wilhelm,et al.  Discovery and development of sorafenib: a multikinase inhibitor for treating cancer , 2006, Nature Reviews Drug Discovery.

[47]  Katherine E. Talcott,et al.  The Role of Therapeutic Angiogenesis in Tissue Repair and Regeneration , 2005, Advances in skin & wound care.

[48]  R. Mckernan,et al.  Discovery of functionally selective 7,8,9,10-tetrahydro-7,10-ethano-1,2,4-triazolo[3,4-a]phthalazines as GABA A receptor agonists at the alpha3 subunit. , 2005, Journal of medicinal chemistry.

[49]  Xiaoyang Xia,et al.  Classification of kinase inhibitors using a Bayesian model. , 2004, Journal of medicinal chemistry.

[50]  J. Folkman.  Role of angiogenesis in tumor growth and metastasis. , 2002, Seminars in oncology.

[51]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[52]  Mamdouh M. Ali,et al.  1-Piperazinylphthalazines as potential VEGFR-2 inhibitors and anticancer agents: Synthesis and in vitro biological evaluation. , 2016, European journal of medicinal chemistry.

[53]  M. Shibuya,et al.  Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. , 2013, Journal of biochemistry.

[54]  P. Seglen.  Preparation of isolated rat liver cells. , 1976, Methods in cell biology.